Site Map

Pages

• About the Hovon 150 Trial
• About us
  • Annual reports and accounts
  • Contact us
    • New South Wales and the Australian Capital Territory
    • Queensland
    • South Australia and Northern Territory
    • Tasmania
    • Victoria
    • Western Australia
  • What we do
    • Our strategy
      • Access to best-practice treatment
      • Access to essential supportive care
      • Access to trusted information
    • Your impact this year
      • Driving faster research answers and better treatments
      • Empowering families
      • Giving strength and support
  • Who we are
    • Our history
    • Our people
  • Working with us
    • Current vacancies
    • Meet our staff
• Blood cancer information
  • Carers and friends
    • Adjusting to being a carer
    • Being a carer
    • Carer resources
    • Carers and the health system
    • Day-to-day caring
    • Financial and legal support for carers
    • Providing support for those with a blood cancer
  • For healthcare professionals
  • Myeloma Awareness Month
  • Real stories
  • The blood cancer journey
    • Grief and loss
      • Getting my affairs in order
        • Accessing superannuation
        • Advance care planning
        • Legal matters
        • Managing your finances
        • Seeking help
        • Useful contacts
      • Grief and loss
      • Palliative care
    • In active treatment
      • Blood cancer treatment options
        • Clinical trials
        • Drug Availability in Australia
        • Other therapies
        • Stem cell transplants
          • Allogeneic stem cell transplants
          • Autologous stem cell transplants
          • COVID-19 and the effect on stem cell donations
          • Haploidentical stem cell transplant
          • Sources of stem cell transplants
        • Supportive care
      • Other side effects
        • Iron overload and iron chelation therapy
        • Osteonecrosis of the jaw
        • Peripheral neuropathy
      • Refractory cancer
      • Wellbeing during treatment
        • Viruses & blood cancer – what you need to know
    • Living well with blood cancer
      • Diet and nutrition
      • Emotional health
        • Mental health
        • Relationships and sex
      • Practical matters
        • Returning to work or study
        • Travel and holidays
        • Useful contacts
    • Newly diagnosed
      • Adolescents and young adults with blood cancer
      • Fertility support
      • Pregnancy with a blood cancer
      • Questions to ask your doctor
      • Telling people about your blood cancer
      • What happens next?
      • Your care team
    • Not in active treatment
      • Life after treatment
  • Types of blood cancer
    • Amyloidosis
      • AL amyloidosis
      • Amyloidosis diagnosis
      • Amyloidosis treatment
        • Side effects of amyloidosis treatment
    • Aplastic anaemia
      • Aplastic anaemia diagnosis
      • Aplastic anaemia treatment
        • Side effects of aplastic anaemia treatment
    • Blood cancer and COVID-19
      • Blood cancer and COVID-19: FAQs
      • Blood Cancer Doesn’t Stop: Our Stories
      • Stay connected
    • Childhood blood cancers
      • Childhood acute lymphoblastic leukaemia (ALL)
        • Childhood ALL diagnosis
        • Childhood ALL treatment
        • Side effects of childhood ALL treatment
      • Childhood acute myeloid leukaemia (AML)
        • Childhood AML diagnosis
      • Childhood AML
        • Childhood AML treatment
          • Side effects of childhood AML treatment
      • Childhood lymphoma
        • Childhood lymphoma diagnosis
        • Childhood lymphoma treatment
          • Side effects of childhood lymphoma treatment
      • Childhood MDS and MPN
        • Childhood MDS and MPN diagnosis
        • Childhood MDS and MPN treatment
          • Side effects of childhood MDS and MPN treatment
      • Children and blood cancer
      • Juvenile myelomonocytic leukaemia (JMML)
        • JMML diagnosis
        • JMML treatment
          • Side effects of JMML treatment
    • Leukaemia
      • Acute lymphoblastic leukaemia (ALL)
        • Acute lymphoblastic leukaemia diagnosis
        • Acute lymphoblastic leukemia treatment
          • Side effects of ALL treatment
      • Acute myeloid leukemia (AML)
        • Acute myeloid leukaemia treatment
          • Side effects of AML treatment
        • Acute myeloid leukemia diagnosis
      • Acute promyelocytic leukaemia (APML)
        • Acute promyelocytic leukaemia diagnosis
        • Acute promyelocytic leukaemia treatment
          • Side effects of APML treatment
      • Biphenotypic leukaemia
      • Chronic lymphocytic leukaemia (CLL)
        • Chronic lymphocytic leukaemia diagnosis
        • Chronic lymphocytic leukemia treatment
          • Side effects of CLL treatment
        • Richter’s Syndrome
      • Chronic myeloid leukaemia (CML)
        • Chronic myeloid leukaemia diagnosis
        • Chronic myeloid leukaemia treatment
          • Side effects of CML treatment
      • Hairy cell
      • Hairy cell leukaemia
        • Hairy cell leukemia diagnosis
        • Hairy cell leukemia treatment
          • Side effects of hairy cell leukaemia treatment
    • Lymphoma
      • Hodgkin lymphoma
        • Hodgkin lymphoma diagnosis
        • Hodgkin lymphoma treatment
          • Side effects of Hodgkin lymphoma treatment
      • Non-Hodgkin lymphoma
        • Adult T-cell lymphoma
        • Anaplastic large cell lymphoma
        • Burkitt’s lymphoma
        • Diffuse large B-cell lymphoma
        • Double hit lymphoma
        • Follicular lymphoma
        • Lymphoblastic lymphoma
        • Mantle cell lymphoma
        • Mucosa-associated lymphoid tissue lymphoma
        • Nodal marginal zone lymphoma
        • Non-Hodgkin lymphoma diagnosis
        • Non-Hodgkin lymphoma treatment
          • Side effects of non-Hodgkin lymphoma treatment
        • Peripheral T-cell lymphoma
        • Primary central nervous system lymphoma
        • Skin lymphomas
        • Small lymphocytic lymphoma
    • Myelodysplastic syndromes (MDS)
      • Chronic myelomonocytic leukaemia
      • Deletion 5q
      • MDS – RARS
      • MDS – RCMD
      • MDS – RCUD
      • Myelodysplastic syndromes diagnosis
      • Myelodysplastic syndromes treatment
        • Side effects of MDS treatment
      • RAEB
    • Myeloma
      • Bisphosphonates
      • Monoclonal gammopathy of unknown significance (MGUS)
      • Myeloma diagnosis
      • Myeloma treatment
        • Side effects of myeloma treatment
      • Solitary plasmacytoma
    • Myeloproliferative neoplasms (MPN)
      • Essential Thrombocythaemia (ET)
      • MPN diagnosis
      • MPN treatment
        • Side effects of MPN treatment
      • Polycythaemia (Rubra) Vera
      • Primary myelofibrosis
    • Understanding your blood
      • Blood cancer facts and figures
      • Blood tests
      • The bone marrow and blood formation
      • The lymphatic system
      • What is blood?
    • Waldenstrom’s macroglobulinaemia (WM)
      • Waldenstrom’s macroglobulinaemia diagnosis
      • Waldenstrom’s macroglobulinaemia treatment
        • Side-effects of Waldenstrom’s macroglobulinaemia treatment
  • World Lymphoma Awareness Day
• Current funding opportunities
  • Cancer Australia Research Grants
  • PhD Scholarships Program
• Disclaimer
  • Site information
• Get involved
  • Become a member
  • Business partnerships
    • Charity Partner of the Year
    • Corporate volunteering
    • In-kind sponsorship
    • Join Lifeblood Heroes at Work
    • Our partners
      • Bridgestone and the Leukaemia Foundation
    • Partner with the Leukaemia Foundation
  • Events
  • Fundraise
    • Create your own fundraiser
    • Join an event
      • Dry July
      • Team Beat Blood Cancer
  • Other ways to get involved
    • Blood Cancer Awareness Month
    • Donate your blood or bone marrow
    • Supporter Seminar Series
  • Volunteer
• Home
• How we can help
  • Accommodation services
    • About our accommodation services
    • Bridgestone Australia Village (Adelaide)
    • Building of Hope (Melbourne)
    • Clem Jones – Sunland Village (Brisbane)
    • ESA Village (Brisbane)
    • Herston Village (Brisbane)
    • John James Village (Canberra)
    • NSW Accommodation
    • Policies and reimbursements
    • Queensland Freemasons Village (Townsville)
    • Village Green Apartments (Brisbane)
    • Western Australia
  • Advocacy and policy
    • Blood Cancer Taskforce
    • National Strategic Action Plan for Blood Cancer
      • About the National Strategic Action Plan for Blood Cancer
    • State of the Nation: Blood Cancer in Australia
    • Working with Governments
  • Assessment and referral services
  • Emotional support services
  • Grief and bereavement support services
  • Health and wellbeing support services
  • Information and education services
    • About our information and education services
    • Disease newsletter archive
    • Download our information booklets
      • Cooking for Chemo recipes
      • Disease information booklets
      • Download resources for children
    • E-newsletters
    • Glossary of terms
    • Podcasts and audio
    • Useful websites
  • Practical support services
  • Support groups
  • Transport services
• Make a donation
  • Become a Lifeblood Hero
  • Donate
  • Donate by phone, post, or direct deposit
  • Focused philanthropy
  • Leave a gift in your Will
    • Gift in Will FAQs
    • Gift in Will stories
    • Will planning checklist
• National Research Program
• National Strategic Action Plan for Blood Cancer
  • Partners for the National Strategic Action Plan for Blood Cancer
• News
  • Media Hub
    • Guidelines for reporting on Blood Cancer in Australia
    • Image and vision library
    • Media contacts
  • Media releases
  • Stories
  • Subscribe to our news
• Notification statement
• Privacy
• Research
  • Current funding opportunities
    • PdCCRS Cancer Australia Grants
    • PhD Scholarships Program
  • National Research Program
    • Cancer Australia PdCCRS recipients
      • Developing a new drug a as a novel therapeutic strategy for aggressive leukaemia in children
      • Developing a new targeted therapy with minimal side effects and toxicity to improve the outcome of childhood AML
      • Developing new models for drug testing to understand the biology and mechanisms of drug resistance in AML
      • Developing new tests to identify which individuals with smouldering myeloma are at risk of developing myeloma
      • Increasing the efficiency while decreasing toxicity of myeloma therapies
      • Studying the interaction between bone and leukaemia cells to improve treatment outcomes in childhood leukaemia
      • Using novel combination therapy to increase the changes of cure for childhood AML
    • Clinical trials
      • Blood Cancer Genomics Trial
      • The Trials Enabling Program (TEP)
        • Clinical trial for Advanced Stage Hodgkin Lymphoma
        • Clinical trial for high tumour burden follicular lymphoma
        • Clinical trial for newly diagnosed AML or MDS with FLT3 mutation
        • Clinical trial for newly diagnosed AML or MDS with IDH1 or IDH2 mutation
        • Trials Enabling Program FAQs
    • LLS Translational Research Program Grant recipients
      • Beyond Azacitidine: Investigating new therapeutic strategies for the treatment of MDS
      • Improving therapy for CRLF2-rearranged Ph-like acute lymphoblastic leukemia
      • Targeting deregulated epigenetic mechanisms in B-cell lymphomas
      • Therapeutic targeting of IRF4 to treat multiple myeloma
    • PhD scholarship recipients
      • Dr Khai Li Chai: 2020 recipient
      • Dr Liesl Butler: 2020 recipient
      • Identifying subclones in early phase MPN that drive progression and leukaemic transformation
      • Investigating the mechanisms by which Tp53 prevents the development of leukaemia, lymphoma
      • Molecular barcoding to understand initiation, maintenance and progression of AML at single cell resolution
      • T-cell immunotherapy for B-cell malignancies and viral infections
      • Targeting the cancer-immune crosstalk in acute myeloid leukaemia (AML)
      • Using antifungal treatments to prevent infection in people with blood cancers and those undergoing bone marrow transplants
      • Using genetic and molecular technologies to better understand follicular lymphoma
    • Strategic Ecosystem Partnership Grant recipients
      • Characterisation of a novel DCAF factor as a blood cancer therapy
      • Deep profiling of ALL and myeloma for targeted therapies
      • Developing state-of-the art molecular genetic testing in cancer diagnosis and monitoring
      • Establishing a new prognostic score for Follicular Lymphoma to rationalise therapeutic decision-making and improve patient outcomes
      • Multiomic analysis in Waldenstrom’s Macroglobulinemia
      • Precision Medicine in acute lymphoblastic leukaemia
      • The Centre for Blood Transplant and Cell Therapy
      • The role of the bone marrow microenvironment in the myeloma plasma cell dormancy and reactivation – toward a cure for myeloma
      • Understanding the process of progression from MDS to acute leukaemia
  • Past research
    • Boosting the immune system response
    • Double discovery – game changer in quest to cure leukaemia
    • Graft v Host disease
    • Investigating factors that may cause genetic changes in leukaemia
    • New drug combination turbo charges attack against cancer
    • Novel drug for treatment of Burkitt’s lymphoma
    • Research project archive
    • Researchers identify gene that could lead to better understanding of MDS
    • Targeting stem cells in myeloproliferative disorders
  • Research in action
• Site map
• Thanks for sharing your story
• Update your details
• Blood Cancer Awareness Month Resources
• Share your blood cancer story
• My Life Counts